The number of women who sought permanent birth control via surgery increased in the wake of Roe v. Wade's overturn in 2022 Researchers saw a 51% increase in tubal ligation in four states “There was a ...
ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...
ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of ...
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product ...
Hosted on MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing
・Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device. ・The company ...
Education on birth control and its potential adverse effects is vital to women choosing the type that best suits them. Skepticism surrounding hormonal birth control has been increasing nationwide, ...
ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY) (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results